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To the Editor: Mycoplasma genitalium is a sexually 
transmitted bacterium involved in nongonococcal urethritis 
in men and associated with cervicitis and pelvic inflamma-
tory disease in women. Azithromycin regimens have been 
commonly used as a first-line treatment of these conditions, 
but a recent increase in M. genitalium with azithromycin re-
sistance has been described worldwide; in 2012, resistance 
in the organism was detected in France at a prevalence of 
14% (1). In case of azithromycin failure, moxifloxacin is 
a second-line treatment; however, moxifloxacin treatment 
failures have also been reported and are associated with 
mutations in ParC or GyrA (2).
Prevalence of M. genitalium infection was ≈4% in 2013–
2014 at Bordeaux University Hospital (Bordeaux, France). 
To evaluate the prevalence of fluoroquinolone resistance 
in M. genitalium in southwestern France, we examined the 
quinolone resistance–determining regions (QRDRs) of the 
gyrA and parC genes in M. genitalium–positive specimens 
obtained during 2013–2014. We retrospectively collected 
(from the Department of Bacteriology, Bordeaux University 
Hospital) 369 M. genitalium–positive urogenital specimens 
and DNA extracts from 344 patients. The gyrA and parC 
QRDRs were amplified and sequenced as described (3,4). 
We also assayed macrolide resistance–associated muta-
tions using real-time PCR and melting curve analysis (1). 
To determine resistant genotypes A2058G or A2059G, we 
sequenced PCR products. Nucleotide positions in the 23S 
rRNA and amino acid positions in GyrA and ParC were iden-
tified according to Escherichia coli numbering.
From the 344 M. genitalium–positive patients, 200 
specimens underwent complete analysis for the gyrA and 
parC genes, specimens from 221 patients were investigated 
for macrolide resistance, and specimens from 168 patients 
were examined for 23S rRNA, gyrA, and parC genes. Un-
successful amplifications could be attributed to low bacte-
rial loads of M. genitalium or to the degradation of frozen 
DNA during storage. Strains from 12/200 patients (6%; 
95% CI 3.47%–10.19%) had QRDR mutations, with rates 
of 6.4% (6/93) for 2013 and 5.6% (6/107) for 2014. This 
prevalence is in accordance with the 4.5% moxifloxacin re-
sistance described in the United Kingdom in 2011 (3) but 
lower than prevalences found in small numbers of strains in 
Japan and Australia during 2006–2014, which ranged from 
10% to 47% (4–8).
Strains from 11 patients (patient nos. 6, 8, 12, 20, 
23, 28–31, 46, 47) harbored alterations in the ParC 
QRDR (Table) at positions 80 (Ser→Asn or Ile) or 
84 (Asp-84→Tyr or Asn). These mutations have been 
previously described for M. genitalium (4,6–8). In addition, 
1 new amino acid alteration, Asn-96→Ser (strain from pa-
tient 20), was found in ParC. We detected a GyrA modifi-
cation with the Ala-93→Thr transition in a strain from 1 
patient (patient 3). These 2 amino acid changes were not 
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previously reported; however, mutations at the next posi-
tions (97 in ParC and 95 in GyrA) have been described 
for M. genitalium (4,7), and these positions are within the 
QRDRs, suggesting their involvement in fluoroquinolone 
resistance. As previously described, M. genitalium ParC al-
terations predominate over GyrA alterations.
None of the 12 patients with strain parC or gyrA muta-
tions had a history of fluoroquinolone treatment. Six patients 
received no treatment; 4 patients received azithromycin 
(1 g); 2 patients received extended azithromycin (1.5 g), 
1 patient after azithromycin (1 g) failure, and 1 after re-
ceiving doxycycline for 7 days. Therapeutic outcomes were 
not available except for 1 patient, who experienced clinical 
failure after 2 azithromycin treatments.
Regarding macrolide resistance, 38 of 221 patients 
(17.20%; 95% CI 12.79%–22.72%) had M. genitalium 
with macrolide resistance–associated 23S rRNA mutations; 
prevalence was 17% (19/112) for 2013 and 17.4% (19/109) 
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Table. Fluoroquinolone resistance–associated amino acid changes in GyrA and ParC and macrolide resistance–associated mutations 
iin the 23S rRNA gene in Mycoplasma genitalium, France, 2013–2014* 
Patient no. Date of collection 
Patient 
sex Specimen type 
Mutation in the 23S 
rRNA gene 
Amino acid changes in 
GyrA ParC 
1 2013 Jan 9 F Vaginal swab A2058G/A2059G NA NA 
2 2013 Feb 1 F Vaginal swab A2058G – – 
3 2013 Feb 1 M Urethral swab A2058G/A2059G Ala-93Thr – 
4 2013 Feb 18 M Urethral swab A2058G/A2059G – – 
5 2013 Feb 20 M Urine A2058G/A2059G – – 
6 2013 Mar 11 M Urine A2058G/A2059G – Asp-84Tyr 
7 2013 Mar 28 F Vaginal swab A2058G/A2059G NA – 
8 2013 Apr 3 M Urine Wild-type – Asp-84Tyr 
9 2013 Apr 8 F Vaginal swab A2058G/A2059G – – 
10 2013 Apr 11 F Vaginal swab A2058G/A2059G NA NA 
11 2013 Apr 16 F Vaginal swab A2058G – NA 
12 2013 Apr 19 F Vaginal swab Wild-type – Ser-80Asn 
13 2013 May 21 M Urethral swab A2059G – – 
14 2013 Jul 4 M Urine A2059G – – 
15 2013 Jul 4 M Urethral swab A2059G – – 
 2013 Jul 19 M Urine A2059G – – 
16 2013 Jul 19 M Urine A2058G – – 
17 2013 Aug 9 F Vaginal swab A2059G NA – 
18 2013 Sep 30 F Vaginal swab A2058G/A2059G – – 
19 2013 Sep 30 F Vaginal swab A2058G/A2059G – – 
20 2013 Oct 29 F Vaginal swab Wild-type – Asn-96Ser 
21 2013 Nov 22 F Vaginal swab A2058G/A2059G NA NA 
22 2013 Nov 29 F Vaginal swab A2062T – – 
23 2013 Dec 1 F Vaginal swab Wild-type – Asp-84Tyr 
24 2014 Jan 21 F Vaginal swab A2059G – – 
25 2014 Jan 29 F Vaginal swab A2059G – – 
26 2014 Jan 30 F Vaginal swab A2058G/A2059G NA – 
27 2014 Feb 13 F Vaginal swab A2059G – – 
28 2014 Feb 18 M Urine Wild-type – Ser-80Ile 
29 2014 Feb 24 F Vaginal swab Wild-type – Asp-84Asn 
30 2014 Mar 5 F Vaginal swab Wild-type – Asp-84Asn 
31 2014 Mar 14 M Urine NA – Ser-80Asn 
32 2014 Apr 3 F Endocervical swab A2058G – – 
33 2014 Apr 7 M Urethral swab A2059G – – 
34 2014 Jun 24 F Vaginal swab A2059C – – 
35 2014 Jul 9 F Endocervical swab A2059G NA – 
36 2014 Jul 25 F Urine A2058G/A2059G NA NA 
37 2014 Jul 25 F Vaginal swab A2058G – – 
38 2014 Aug 19 F Endocervical swab A2062T – NA 
39 2014 Aug 28 F Vaginal swab A2058G/A2059G – – 
40 2014 Sep 24 F Vaginal swab A2059G – – 
41 2014 Oct 7 F Vaginal swab A2059G – – 
42 2014 Oct 15 F Vaginal swab A2058G/A2059G – – 
43 2014 Oct 31 M Urine A2058G – – 
44 2014 Nov 5 F Vaginal swab A2058G/A2059G NA – 
45 2014 Nov 28 F Vaginal swab A2058G – – 
46 2014 Dec 3 F Vaginal swab Wild-type – Asp-84Asn 
47 2014 Dec 3 M Urethral swab Wild-type – Asp-84Asn 
48 2014 Dec 4 M Urine A2059G – – 
*A2058/A2059G indicates a macrolide–resistant (A2058G or A2059G) genotype. Positions in the 23S rRNA and in GyrA and ParC are 
identified according to Escherichia coli numbering. NA, not available;  –, no amino acid change.  
 
for 2014. This prevalence is increasing compared to that 
described in France in 2012 (14%). We found 35 A→G 
substitutions at position 2058 or 2059, two A2062T mu-
tations and one A2059C mutation (Table) (1,9). Notably, 
in patients 15 and 33, who were infected with strains with 
macrolide resistance–associated mutations, M. genitalium 
infection was unsuccessfully treated with azithromycin, 
with treatment failures after azithromycin (1 g) and extend-
ed azithromycin (1.5 g for 5 d), but moxifloxacin treatment 
was effective. Patient 15 had been treated 1 year earlier 
with azithromycin (1 g) for nongonococcal urethritis.
Among the 168 patients whose isolates were exam-
ined for the 23S rRNA, gyrA, and parC genes, strains 
from 2 patients (patients 3 and 6) had both macrolide- 
and fluoroquinolone-associated mutations (1.2%; 95% CI 
0.33%–4.24%). Both patients received azithromycin (1 
g), and patient 6 received additional azithromycin (1.5 g) 
after failure of azithromycin (1 g). Patient 6 experienced 
azithromycin failure again after the extended regimen. M. 
genitalium multidrug resistance is described in France at 
a prevalence of 1.2%, lower than prevalence described in 
Australia (7.5%) (7) and Japan (30.8%) (10).
In conclusion, M. genitalium fluoroquinolone resistance 
is emerging in France, with a prevalence of 6% in 2013–
2014. Further, macrolide resistance also increased during 
this period, to a rate of 17.2%. Patients infected with M. gen-
italium strains containing both macrolide and fluoroquino-
lone resistance mutations associated with therapeutic failure 
raise concerns about untreatable M. genitalium infections.
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To the Editor: Plasmid-mediated, colistin-resistance 
mechanism gene mcr-1 was first identified in Escherichia 
coli isolates from food, food animals, and human patients 
in November 2015 (1). Reports on detection of mcr-1 
in Enterobacteriaceae from humans and food animals 
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